Skip to product information
1 of 6

Brand Baiyunshanxingqun. Lianbenshuangzhi Diwan or Lianbenshuangzhi Dripping Pills or Lianben Shuangzhi Diwan or Bifendate Pills For Hepatitis

Brand Baiyunshanxingqun. Lianbenshuangzhi Diwan or Lianbenshuangzhi Dripping Pills or Lianben Shuangzhi Diwan or Bifendate Pills For Hepatitis

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Shipping calculated at checkout.
Options

联苯双酯滴丸

Generic name: Bifendate pills
Chinese Pinyin: Lianbenshuangzhi Diwan
English name: Bifendate Pills
Product name: Star Group
Ingredients: Bifendate. Its chemical name is: 4, 4'-Dimethoxy-5, 6, 5', 6'-secondary dimethyl dioxy-2, 2'-dicarboxylic acid methyl biphenyl.
Properties: This product is sugar-coated dripping pills
Indications: Clinically used for patients with chronic persistent hepatitis with elevated ALT, and can also be used for elevated ALT caused by chemical poisons and drugs.
Specification: 1.5mg*250 tablets/bottle
Usage and Dosage: Oral: Dropping pills, 5 capsules/time, 3 times a day, if necessary, 6-10 capsules/time, 3 times a day, 3 months, after ALT is normal, change to 5 capsules/time, 3 times a day, Even serving March. Oral for children: 0.5mg/kg, 3 times a day for 3 to 6 months.
Adverse reactions: Dry mouth, mild nausea, and occasional skin rashes may occur in individual cases, which usually disappear after adding anti-allergic drugs.
Taboo: People who are allergic to this product should not be used. It is forbidden for patients with decompensated liver cirrhosis, and for pregnant and lactating women.
Note: 1. In a few patients, ALT can rise during medication, and it can be reduced by increasing the dose. After stopping the drug, some patients' ALT rebounded, but continued to take the drug is still effective.
2. Individual patients may develop jaundice and worsen their condition during the course of taking the medication, and the medication should be discontinued.
Drug interactions: Combined use of inosine can reduce the enzyme-lowering rebound of this product.
Pharmacology and Toxicology: This product is an enzyme-lowering drug for the treatment of hepatitis created in my country, and is an intermediate in the synthesis of Schisandrin C. Mice oral administration of 150~200mg/kg of this product can reduce liver damage and alanine aminotransferase (ALT) elevation caused by carbon tetrachloride. It has an inhibitory effect on liver microsomal lipid peroxidation caused by carbon tetrachloride and the conversion of carbon tetrachloride to carbon monoxide, and reduces the consumption of reduced coenzyme II and oxygen in the process of carbon tetrachloride metabolism, thereby protecting liver cells The structure and function of biofilms. This product can also reduce the elevation of liver ALT induced by prednisone, and can promote liver regeneration in mice with partial hepatectomy. The enzyme-lowering effect of this product does not directly inhibit the activity of serum and liver ALT, nor does it accelerate the inactivation of ALT in the blood. It may be a reflection of the reduction of liver tissue damage. This product has a significant inducing effect on cytochrome P450 enzyme activity, thereby enhancing the detoxification ability of carbon tetrachloride and certain carcinogens. It can improve protein metabolism in some patients with hepatitis, increase albumin and decrease globulin. It has no negative effect on HbsAg and HbeAg, nor can it shrink the enlarged liver and spleen.
Pharmacokinetics: Oral absorption of this product is about 30%, and it is rapidly transformed by metabolism under the first pass of the liver. About 70% is excreted in feces within 24 hours. The bioavailability of dripping pills is 1.25 to 2.37 times that of tablets.
Medication for pregnant women and breastfeeding women: contraindicated by pregnant women and breastfeeding women
Child medication: Decrease the dose of medication for children.
Medication for elderly patients: Use this product with caution in elderly patients
Overdose: Unclear
Storage: Airtight, store in a dry place (10-30 degrees Celsius).
Packaging: Packed in plastic bottles, 250 capsules per bottle
Validity period: 36 months
Executive standard: "Chinese Pharmacopoeia" (2010 edition two)
Approval number: National Medicine Zhunzi H44023176
Company Name: Guangzhou Xingqun (Pharmaceutical Industry) Co., Ltd.

View full details